Nitroxyl (HNO) acts as an effective inhibitor of human platelet aggregation, demonstrating similar antiaggregatory effects to nitric oxide.
No takes yet. Share an insight, caveat, or question.
Nitroxyl donors may inhibit platelet aggregation ex vivo; leaves open antithrombotic potential pending in vivo validation.
Bermejo et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: